Moderna Inc (NASDAQ:MRNA) Expected to Post Quarterly Sales of $15.03 Million

Wall Street brokerages expect that Moderna Inc (NASDAQ:MRNA) will report sales of $15.03 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Moderna’s earnings, with the lowest sales estimate coming in at $13.08 million and the highest estimate coming in at $17.00 million. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 6th.

According to Zacks, analysts expect that Moderna will report full year sales of $88.72 million for the current year, with estimates ranging from $55.27 million to $143.20 million. For the next year, analysts forecast that the firm will report sales of $79.75 million, with estimates ranging from $10.55 million to $132.50 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Moderna.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.01. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $18.80 million.

A number of analysts have recently issued reports on the stock. Morgan Stanley set a $30.00 price target on shares of Moderna and gave the stock a “buy” rating in a report on Friday, August 9th. Oppenheimer raised their price target on shares of Moderna from $27.00 to $31.00 and gave the stock an “outperform” rating in a report on Wednesday, May 29th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of Moderna in a report on Monday, August 12th. Chardan Capital restated a “buy” rating on shares of Moderna in a report on Sunday, September 15th. Finally, JPMorgan Chase & Co. restated a “buy” rating and set a $24.00 price target on shares of Moderna in a report on Sunday, August 11th. Ten investment analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $26.30.

Shares of NASDAQ MRNA traded up $0.17 during midday trading on Thursday, reaching $18.07. 6,517,157 shares of the stock were exchanged, compared to its average volume of 3,002,093. The firm has a 50 day moving average of $14.67. The stock has a market cap of $5.91 billion and a PE ratio of -3.65. Moderna has a twelve month low of $11.54 and a twelve month high of $29.79.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Recommended Story: Benefits of owning preferred stock

Get a free copy of the Zacks research report on Moderna (MRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.